The Janssen Pharmaceutical Companies of Johnson & Johnson on February 8, 2018, announced U.S. Food and Drug Administration (FDA) approval of a new indication for Zytiga (abiraterone acetate) in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer (CSPC).
Read Corporate Press Release
Posted 2/8/18
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
